BR112018007304A2 - terapia de combinação para tratamento de malignidades - Google Patents

terapia de combinação para tratamento de malignidades

Info

Publication number
BR112018007304A2
BR112018007304A2 BR112018007304A BR112018007304A BR112018007304A2 BR 112018007304 A2 BR112018007304 A2 BR 112018007304A2 BR 112018007304 A BR112018007304 A BR 112018007304A BR 112018007304 A BR112018007304 A BR 112018007304A BR 112018007304 A2 BR112018007304 A2 BR 112018007304A2
Authority
BR
Brazil
Prior art keywords
malignancies
treatment
combination therapy
lma
combination
Prior art date
Application number
BR112018007304A
Other languages
English (en)
Portuguese (pt)
Inventor
V Agresta Samuel
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of BR112018007304A2 publication Critical patent/BR112018007304A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112018007304A 2015-10-15 2016-10-14 terapia de combinação para tratamento de malignidades BR112018007304A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US201562255194P 2015-11-13 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (1)

Publication Number Publication Date
BR112018007304A2 true BR112018007304A2 (pt) 2018-10-23

Family

ID=57208385

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007304A BR112018007304A2 (pt) 2015-10-15 2016-10-14 terapia de combinação para tratamento de malignidades

Country Status (15)

Country Link
US (2) US10905692B2 (enExample)
EP (2) EP3362057A1 (enExample)
JP (2) JP2018534288A (enExample)
KR (2) KR20250065944A (enExample)
CN (1) CN108366980A (enExample)
AU (1) AU2016340087C1 (enExample)
BR (1) BR112018007304A2 (enExample)
CA (1) CA3001599A1 (enExample)
CL (1) CL2018000927A1 (enExample)
EA (1) EA201890968A1 (enExample)
IL (2) IL311873A (enExample)
MX (2) MX394796B (enExample)
SG (1) SG10201912886XA (enExample)
WO (1) WO2017066599A1 (enExample)
ZA (1) ZA201802088B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
EP3362070B1 (en) 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
BR112019004356A2 (pt) 2016-09-07 2019-05-28 Celgene Corporation composições de comprimido
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
JP7305613B2 (ja) * 2017-07-09 2023-07-10 バイオサイト リミテッド 併用がん療法
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
CN115243690A (zh) 2019-11-14 2022-10-25 新基公司 用于治疗癌症的儿科制剂
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
EP3019490B1 (en) 2013-07-11 2020-06-03 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
EA030428B1 (ru) 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
EP3362070B1 (en) 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
EP3383400B1 (en) 2015-12-04 2022-01-05 Les Laboratoires Servier Methods of treatment of malignancies
MX390396B (es) 2016-02-26 2025-03-20 Celgene Corp Enasidenib para usarse en leucemia mieloide aguda recidivante o refractaria.

Also Published As

Publication number Publication date
IL258269A (en) 2018-05-31
KR20180063125A (ko) 2018-06-11
IL311873A (en) 2024-06-01
US20180311249A1 (en) 2018-11-01
AU2016340087C1 (en) 2022-08-18
NZ740792A (en) 2024-05-31
KR20250065944A (ko) 2025-05-13
US10905692B2 (en) 2021-02-02
WO2017066599A1 (en) 2017-04-20
SG10201912886XA (en) 2020-02-27
JP2021130682A (ja) 2021-09-09
AU2016340087B2 (en) 2022-05-12
AU2016340087A1 (en) 2018-04-12
MX394796B (es) 2025-03-24
MX2022006701A (es) 2022-07-12
MX2018004595A (es) 2019-07-04
EP3362057A1 (en) 2018-08-22
CL2018000927A1 (es) 2018-09-14
CN108366980A (zh) 2018-08-03
EA201890968A1 (ru) 2018-09-28
EP4147692A1 (en) 2023-03-15
US20210386749A1 (en) 2021-12-16
CA3001599A1 (en) 2017-04-20
JP2018534288A (ja) 2018-11-22
ZA201802088B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
BR112018007304A2 (pt) terapia de combinação para tratamento de malignidades
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2018006745A (es) Metodos de tratamiento de neoplasias malignas.
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
CL2015002807A1 (es) Terapia de combinación
BR112017004826A2 (pt) terapias de combinação de inibidores de alk
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
MX383484B (es) Método para tratar el cáncer.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2024014237A (es) Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
MX2018002344A (es) Metodo para tratar el cancer.
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
BR112018013928A2 (pt) composições terapêuticas e métodos para tratamento da hepatite b
BR112019008241A2 (pt) tratamento do prurigo nodular
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MY200803A (en) Mpo inhibitors for use in medicine
BR112018076935A2 (pt) composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia
EA201890956A1 (ru) Комбинированная терапия для лечения злокачественных опухолей

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]